Clinical trial · Interventional
MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies
NCT06543511CI-TRIAL-00082922withdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Contractual issues. Will be re-submitted as new protocol.
Summary
Brief summary (as posted)
This research study is evaluating the feasibility of conducting cancer genetic testing using healthy skin cells among participants with a diagnosis of a blood cancer. Additionally, investigators will evaluate how often participants with blood cancers are found to have risk for cancer based on family genes.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Blood Cancer | Liquid Tumor | ALIAS | 0.90 |
| Myeloid Malignancies | — | UNRESOLVED | — |
| Myeloid Malignancy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Genetic Blood Test | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Germline Genetic Testing
- description
- Participants will be enrolled and will complete study procedures as follows: * Baseline visit with educational video and questionnaires. * Skin punch biopsy. * Genetic testing results. * Surveys and questionnaires. * Follow up via medical records for up to 2 years from time of study consent.
- interventionNames
- Other: Genetic Blood Test
Primary outcomes (2)
- measure
- Genetic Testing Completion Rate
- timeFrame
- Up to 63 months
- description
- Feasibility is defined as a minimum of 75% of consented participants complete germline genetic testing with the return of test results within 10 weeks of study consent.
- measure
- Incidence Rate of Positive Genetic Results
- timeFrame
- Up to 63 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age of 18 years or older * Participants must have histologically confirmed myeloid malignancy OR bone marrow failure within the last 6 months prior to screening. * Ability to understand and provide a signed and completed consent document in English or Spanish. Exclusion Criteria: * Patients with who cannot safely undergo skin biopsy as adjudicated by the study team. * Patients who have previously undergone germline genetic testing for predisposition to myeloid malignancies
References
Publications (0)
Data not yet available
No reference posted for this study.